Silver Book Fact

Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.

Romond E, Perez E, Bryant J, Suman V, et al. Tastuzumab Plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer. NEJM. 2005; 353: 1673-84. http://www.nejm.org/doi/full/10.1056/NEJMoa052122

Reference

Title
Tastuzumab Plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer
Publication
NEJM
Publication Date
2005
Authors
Romond E, Perez E, Bryant J, Suman V, et al.
Pages
1673-84
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Close to one third of all drugs currently in the biopharmaceutical pipeline are for cancer, with around 5,500 potential first-in-class cancer medicines in development.  
  • “Among women age 65 and over, the percentage who had a mammogram within the preceding 2 years almost tripled from 23% in 1987 to 64% in 2005.”  
  • 5-Year Relative Survival Rates for Cancers in U.S.  
  • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets late-stage metastatic melanoma. The medicine contains a gene encoding antigen that may be able to…  
  • A drug that can reduce the risk of breast cancer in high-risk women costs approximately $1,050 per year. The average cost per year for surgery or other invasive methods of…